BRAINSTORM CELL THERAPEUTICS INC. financial data

Symbol
BCLI on OTC
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 13% % -49%
Debt-to-equity -132% % 25%
Return On Equity 150% % -47%
Return On Assets -464% % -24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,034,775 shares 93%
Common Stock, Shares, Outstanding 11,034,775 shares 108%
Entity Public Float $25,547,414 USD
Common Stock, Value, Issued $16,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 11,008,047 shares 107%
Weighted Average Number of Shares Outstanding, Diluted 11,008,047 shares 107%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,046,000 USD 9.1%
General and Administrative Expense $5,852,000 USD -33%
Operating Income (Loss) $10,898,000 USD 18%
Net Income (Loss) Attributable to Parent $10,846,000 USD 24%
Earnings Per Share, Basic -1 USD/shares 80%
Earnings Per Share, Diluted -1 USD/shares 80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,000 USD -97%
Assets, Current $508,000 USD 40%
Property, Plant and Equipment, Net $283,000 USD -43%
Operating Lease, Right-of-Use Asset $334,000 USD -65%
Other Assets, Noncurrent $872,000 USD -48%
Assets $1,380,000 USD -32%
Accounts Payable, Current $6,420,000 USD 39%
Employee-related Liabilities, Current $1,876,000 USD 80%
Accrued Liabilities, Current $350,000 USD -60%
Liabilities, Current $9,023,000 USD 27%
Operating Lease, Liability, Noncurrent $50,000 USD -82%
Liabilities $9,073,000 USD 12%
Retained Earnings (Accumulated Deficit) $234,509,000 USD -4.8%
Stockholders' Equity Attributable to Parent $7,693,000 USD -27%
Liabilities and Equity $1,380,000 USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,283,000 USD 36%
Net Cash Provided by (Used in) Financing Activities $313,000 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 11,034,775 shares 108%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $113,000 USD 87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $236,000 USD -32%
Deferred Tax Assets, Valuation Allowance $56,239,000 USD 11%
Deferred Tax Assets, Gross $56,239,000 USD 11%
Operating Lease, Liability $326,000 USD -61%
Depreciation $204,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid $336,000 USD -63%
Property, Plant and Equipment, Gross $3,437,000 USD -0.35%
Operating Lease, Liability, Current $276,000 USD -52%
Lessee, Operating Lease, Liability, to be Paid, Year Two $188,000 USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year One $207,000 USD -63%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10,000 USD -82%
Operating Lease, Payments $171,000 USD 3%